Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.30 |
| ▸ | ANPEP | P15144 | 2/20 | 0.30 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.30 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6545832 | 0.85 | KDM4E (0.34) | KDM4ELPAR2LPAR3 | |
| SCHEMBL6545926 | 0.81 | GAA (0.38) | ALDH1A1KDM4ERAB9APLA2G2D | |
| SCHEMBL3885797 | 0.81 | ALDH1A1 (0.40) | ALDH1A1KDM4ELPAR2LPAR3NPC1 | |
| SCHEMBL6545094 | 0.77 | MAPT (0.34) | ALDH1A1KDM4ENPC1POLBRAB9A | |
| SCHEMBL778515 | 0.76 | TSHR (0.47) | ALDH1A1KDM4ELPAR2LPAR3PTK2B | |
| SCHEMBL28334824 | 0.73 | THRA (0.41) | ALDH1A1TSHRPLA2G2D | |
| SCHEMBL6546173 | 0.73 | GABRA1 (0.38) | ALDH1A1KDM4ENPC1POLBPTK2B | |
| SCHEMBL28332945 | 0.73 | ALDH1A1 (0.41) | ALDH1A1KDM4ETSHRALOX15MAPT | |
| SCHEMBL28332722 | 0.71 | THRA (0.48) | PLA2G2D | |
| SCHEMBL7770815 | 0.68 | CYP4F2 (0.41) | ALDH1A1KDM4ETSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379533-A2 | NOVEL CYCLO AZAPHOSPHA HYDROCARBONS | Leo Pharma A/S (DK) | 2004-01-14 | — | — | EP | disclosed |
| US-6605742-B2 | Rheumatic diseases; antiarthritic agents; antitumor agents | LEO PHARMA A/S (DK) | 2003-08-12 | — | — | US | disclosed |
| US-20020177706-A1 | Novel cyclo azaphospha hydrocarbons | LEO PHARMA A/S (DK) | 2002-11-28 | — | — | US | disclosed |
| WO-2002083696-A2 | NOVEL CYCLO AZAPHOSPHA HYDROCARBONS | LEO PHARMA A/S (DK) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177706-A1 | Novel cyclo azaphospha hydrocarbons | CMA1, MMP9, CPA1 | ALDH1A1 1152/4885KDM4E 1569/4885LPAR2 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.